Christian Scheffold

6.1k citations

75 papers · 2.3k indexed · 1 hit paper · h-index 25

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Pulmonary and Respiratory Medicine top 2%
- Renal cell carcinoma treatment

Papers in

Oncology 44
- Pancreatic and Hepatic Oncology Research 17
- Cancer Immunotherapy and Biomarkers 11
Pulmonary and Respiratory Medicine 45
- Renal cell carcinoma treatment 31

Co-authors: Toni K. Choueiri Robert S. Negrin Robert J. Motzer Matthias Edinger Thomas Leemhuis Bernard Escudier Thomas Powles Geoffrey I. Shapiro
Journals: Journal of Clinical Oncology (26 papers)European Journal of Cancer (6 papers)Blood (4 papers)Annals of Oncology (3 papers)European Urology (3 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

Christian Scheffold

74 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial 2022 · 177 citations

Peers

Countries citing papers authored by Christian Scheffold

Since Specialization

Citations

This map shows the geographic impact of Christian Scheffold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian Scheffold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian Scheffold more than expected).

Fields of papers citing papers by Christian Scheffold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christian Scheffold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian Scheffold. The network helps show where Christian Scheffold may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Christian Scheffold, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christian Scheffold Line = papers co-authored together Christian Scheffold links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study JTO Clinical and Research Reports ·Joel W. Neal, Armando Santoro, María González‐Cao, Farah Louise Lim, Bruno Fang, Ryan D. Gentzler, Jerome H. Goldschmidt, Felipe Concha, Claudia Proto, Shiven B. Patel, Sonam Puri, Stephen V. Liu, Erminia Massarelli, R. Sessiz Ak, S. D. Loss, Christian Scheffold, 曹世静, Enriqueta Felip	2024	2
2	Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial ESMO Open ·Thomas Powles, Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, Diego Fernando González Lozano, 中田和直, Robert J. Motzer, Toni K. Choueiri	2024	31
3	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma BMC Cancer ·Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta K. Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn N. Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George	2021	12
4	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma Työväentutkimus Vuosikirja ·Nizar M. Tannir, Thomas Powles, Bernard Escudier, Frede Donskov, Viktor Grünwald, Cora N. Sternberg, Manuela Schmidinger, Patrick Schöffski, Cezary Szczylik, Rebecca Hägg, Dmitry Nosov, Bohuslav Melichar, Douglas O. Clary, Christian Scheffold, Robert J. Motzer, Toni K. Choueiri	2019	1
5	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update European Journal of Cancer ·Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben L. Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Daniel J. George, Michael J. Morris	2018	267
6	Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma British Journal of Cancer ·Robert J. Motzer, Bernard Escudier, Thomas Powles, Christian Scheffold, Toni K. Choueiri	2018	51
7	Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) Annals of Oncology ·Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Dakhil, Christian Scheffold, Daniel J. George, Michael J. Morris	2017	12
8	Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC) Annals of Oncology ·David Cella, Bernard Escudier, Nizar M. Tannir, Thomas Powles, Frede Donskov, Katriina Peltola, Manuela Schmidinger, D.Y.C. Heng, Paul N. Mainwaring, Hans J. Hammers, Jia-Lin Lee, Brian I. Rini, Bruce J. Roth, John E. Baer, Milan Mangeshkar, Christian Scheffold, Thomas E. Hutson, Sumanta K. Pal, Robert J. Motzer, Toni K. Choueiri	2016	3
9	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort European Urology ·Ethan Basch, Karen A. Autio, Matthew R. Smith, Antonia V. Bennett, Aaron Weitzman, Christian Scheffold, Christopher J. Sweeney, Dana E. Rathkopf, David C. Smith, Daniel J. George, Celestia S. Higano, Andrea Harzstark, Oliver Sartor, Michael S. Gordon, Nicholas J. Vogelzang, Johann S. de Bono, Naomi B. Haas, Paul G. Corn, Frauke Schimmöller, Howard I. Scher	2014	31
10	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Geoffrey I. Shapiro, Jordi Rodón, Cynthia Bedell, Eunice L. Kwak, José Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, Alexander Laird, Linh T. Nguyen, Yi Xu, Coumaran Égile, Gerald M. Edelman	2013	123
11	Abstract B247: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced solid tumors Molecular Cancer Therapeutics ·Jennifer J. Wheler, Anne M. Traynor, Howard H. Bailey, Steven Attia, Gerald S. Falchook, Alexander Laird, Linh T. Nguyen, Christian Scheffold, Razelle Kurzrock	2009	3
12	The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab Cytotherapy ·Martin Kornacker, Michael R. Verneris, L T Lobl, Tom M. Ganten, Christian Scheffold, Robert S. Negrin	2006	6
13	A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma Biology of Blood and Marrow Transplantation ·Thomas Leemhuis, Yvette Lam-Tsai, Christian Scheffold, Matthias Edinger, Robert S. Negrin	2005	184
14	Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells Biology of Blood and Marrow Transplantation ·Christian Scheffold, A Manikandan, Thai M. Cao, Mirkomil Gudalov, Judith A. Shizuru	2004	11
15	Generation of Melanoma-Specific Cytotoxic T Lymphocytes for Allogeneic Immunotherapy Journal of Immunotherapy ·Alena Gryshchenko, Christian Scheffold, X. S. Zhang, Kethelen Tamara Braga Barbosa, Joachim L. Schultze, 穆守刚, Wolfgang E. Berdel, Joachim Kienast	2003	8
16	Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. PubMed ·Christian Scheffold, Martin Kornacker, A Manikandan, Christopher H. Contag, Robert S. Negrin	2002	38
17	Resistance of Pancreatic Carcinoma Cells Is Reversed by Coculturing NK-like T Cells with Dendritic Cells Pulsed with Tumor-Derived RNA and CA 19-9 Molecular Therapy ·Carsten Ziske, Angela Märten, Björn Schöttker, Peter Buttgereit, Frank Schakowski, Chih-Tien Liu, Alexander von Rücker, Christian Scheffold, Nelson J. Chao, Tilman Sauerbruch, Ingo G.H. Schmidt‐Wolf	2001	26
18	Establishment and Characterization of Colon Carcinoma and Renal Cell Carcinoma Primary Cultures Cancer Biotherapy and Radiopharmaceuticals ·Beate Trojaneck, Fukunaga Jyunichi, Diāna Pauna, Petja Lefterova, Rainer Blasczyk, Christian Scheffold, D. Huhn, Ingo G.H. Schmidt‐Wolf	2000	6
19	Targeting of Natural Killer-Like T Immunologic Effector Cells Against Leukemia and Lymphoma Cells by Reverse Antibody-Dependent Cellular Cytotoxicity Journal of Immunotherapy ·Petja Lefterova, Angela Märten, Peter Buttgereit, Laili Ramadhani Puji Rahayu, Christian Scheffold, D. Huhn, Ingo Schmidt‐Wolf	2000	12
20	Induction of Apoptosis in B Lymphoma Cells by Activation with CD40L Acta Haematologica ·Petja Lefterova, Angela Märten, 徐益民, Frank Schakowski, Diāna Pauna, Christian Scheffold, Ingo G.H. Schmidt‐Wolf	2000	2

About Christian Scheffold

Christian Scheffold is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hematology, Immunology and Cancer Research, having authored 75 papers that have together received 2.3k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (31 papers), Pancreatic and Hepatic Oncology Research (17 papers), Renal and related cancers (15 papers), Cancer Immunotherapy and Biomarkers (11 papers), Cancer Genomics and Diagnostics (11 papers), Immune Cell Function and Interaction (10 papers), T-cell and B-cell Immunology (10 papers) and Economic and Financial Impacts of Cancer (8 papers). The work is most often cited by research in Oncology (1.0k citations), Pulmonary and Respiratory Medicine (1.0k citations), Hematology (346 citations), Cancer Research (431 citations) and Genetics (277 citations). Christian Scheffold has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Toni K. Choueiri, Robert S. Negrin, Robert J. Motzer, Matthias Edinger, Thomas Leemhuis, Bernard Escudier, Thomas Powles, Geoffrey I. Shapiro, Eric J. Small and Joachim Kienast. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Blood, Annals of Oncology and European Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact